{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:10:57Z","timestamp":1788585057469,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xops.2026.101129","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:18:05Z","timestamp":1772122685000},"page":"101129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Na\u00efve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study"],"prefix":"10.1016","volume":"6","author":[{"given":"Patricio G.","family":"Schlottmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9568-3558","authenticated-orcid":false,"given":"Amani A.","family":"Fawzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Dieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Glittenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-2590","authenticated-orcid":false,"given":"Chirag","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kotak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8342-5976","authenticated-orcid":false,"given":"Florie","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7467-9947","authenticated-orcid":false,"given":"Veeral S.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0276-1778","authenticated-orcid":false,"given":"Audrey","family":"Souverain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Titz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vazquez-Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-0581","authenticated-orcid":false,"given":"Focke","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-9967","authenticated-orcid":false,"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101129_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib2","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.2147\/OPTH.S281501","article-title":"Real-world outcomes in patients with diabetic macular edema treated long term with ranibizumab (VISION study)","volume":"14","author":"Van Aken","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib3","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/bjophthalmol-2016-308388","article-title":"Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature","volume":"100","author":"Ashraf","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib4","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.2147\/OPTH.S231801","article-title":"Angiopoietins as potential targets in management of retinal disease","volume":"15","author":"Khanani","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaophthalmol.2017.6565","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial","volume":"136","author":"Bressler","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xops.2026.101129_bib9","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2026.101129_bib10","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/jcm13102778","article-title":"Beyond VEGF: angiopoietin-Tie signaling pathway in diabetic retinopathy","volume":"13","author":"Chen-Li","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2026.101129_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","article-title":"The angiopoietin\/Tie pathway in retinal vascular diseases: a review","volume":"41","author":"Heier","year":"2021","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101129_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101129_bib13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101129_bib14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.oret.2024.11.015","article-title":"Resolution of angiographic macular leakage with faricimab versus aflibercept in patients with diabetic macular edema in YOSEMITE\/RHINE","volume":"9","author":"Goldberg","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101129_bib15","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1097\/IAE.0000000000004572","article-title":"Impact of faricimab versus aflibercept on epiretinal membrane formation over 2 years in patients with diabetic macular edema in the phase 3 Yosemite and Rhine trials","volume":"45","author":"Jaffe","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.xops.2026.101129_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ophtha.2024.11.023","article-title":"Anatomic outcomes with faricimab vs aflibercept in head-to-head dosing phase of the TENAYA\/LUCERNE trials in neovascular age-related macular degeneration","volume":"132","author":"Cheung","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101129_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.oret.2025.01.017","article-title":"Anatomic control with faricimab versus aflibercept in the YOSEMITE\/RHINE trials in diabetic macular edema","volume":"9","author":"Lim","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.xops.2026.101129_bib18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100798","article-title":"Effect of faricimab versus aflibercept on hyperreflective foci in patients with diabetic macular edema from the YOSEMITE\/RHINE trials","volume":"5","author":"Chakravarthy","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2026.101129_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00417-004-0950-7","article-title":"Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients","volume":"243","author":"Funatsu","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.eye.6702498","article-title":"Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion","volume":"22","author":"Noma","year":"2008","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2026.101129_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.13.6.17","article-title":"Implications of ocular confounding factors for aqueous humor proteomic and metabolomic analyses in retinal diseases","volume":"13","author":"Titz","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101129_bib23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.12.11.9","article-title":"Correlation of aqueous, vitreous, and serum protein levels in patients with retinal diseases","volume":"12","author":"Wilson","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101129_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/tvst.13.12.23","article-title":"Multi-omics integration with machine learning identified early diabetic retinopathy, diabetic macula edema and anti-VEGF treatment response","volume":"13","author":"Pang","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.xops.2026.101129_bib25","article-title":"Aqueous humor cytokine levels in patients with diabetic macular edema refractory to anti-VEGF treatment","volume":"13","author":"Kwon","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101129_bib26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.survophthal.2022.07.008","article-title":"Role of inflammatory cells in pathophysiology and management of diabetic retinopathy","volume":"67","author":"Kovoor","year":"2022","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222364","article-title":"Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant","volume":"14","author":"Choi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.xops.2026.101129_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ajo.2019.04.002","article-title":"Aqueous humor cytokines and long-term response to anti-vascular endothelial growth factor therapy in diabetic macular edema","volume":"206","author":"Felfeli","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.65.5.26","article-title":"Intraretinal hyper-reflective foci are almost universally present and co-localize with intraretinal fluid in diabetic macular edema","volume":"65","author":"von Schulthess","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101129_bib30","first-page":"4886","article-title":"Impact of early intraretinal fluid reduction on one-year outcomes in diabetic macular edema","volume":"65","author":"Wang","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101129_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.889647","article-title":"Technical performance evaluation of olink proximity extension assay for blood-based biomarker discovery in longitudinal studies of Alzheimer\u2019s disease","volume":"13","author":"Carlyle","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.xops.2026.101129_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xops.2026.101129_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/432685","article-title":"The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases","volume":"2014","author":"Ascaso","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.xops.2026.101129_bib34","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00198.2002","article-title":"E-selectin-inducing activity in plasma from type 2 diabetic patients with maculopathy","volume":"284","author":"Knudsen","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.xops.2026.101129_bib35","article-title":"Endocan: a key player of cardiovascular disease","volume":"8","author":"Chen","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.xops.2026.101129_bib36","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2018.02664","article-title":"Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population","volume":"9","author":"Gaya da Costa","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.xops.2026.101129_bib38","first-page":"6241","article-title":"Real-world clinical and anatomical outcomes in patients with diabetic macular edema treated with faricimab: the FARETINA-DME study","volume":"65","author":"Borkar","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101129_bib39","first-page":"6259","article-title":"The real-world efficacy and safety of faricimab in diabetic macular edema: the TAHOE study","volume":"65","author":"Khan","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101129_bib40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s10384-023-00979-8","article-title":"Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial","volume":"67","author":"Shimura","year":"2023","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcjo.2022.03.003","article-title":"Impact of retinal fluid in patients with diabetic macular edema treated with anti-VEGF in routine clinical practice","volume":"58","author":"Kalur","year":"2023","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101129_bib42","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.3390\/jcm13237426","article-title":"Molecular-genetic biomarkers of diabetic macular edema","volume":"13","author":"Andres-Blasco","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2026.101129_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.preteyeres.2017.10.006","article-title":"Mechanisms of macular edema: beyond the surface","volume":"63","author":"Daruich","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.xops.2026.101129_bib44","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.xops.2026.101129_bib45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nm1351","article-title":"Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation","volume":"12","author":"Fiedler","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.xops.2026.101129_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/nyas.12726","article-title":"Angiopoietin-2: a multifaceted cytokine that functions in both angiogenesis and inflammation","volume":"1347","author":"Scholz","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.xops.2026.101129_bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.13.11.13","article-title":"Ocular pharmacodynamics of intravitreal faricimab in patients with neovascular age-related macular degeneration or diabetic macular edema","volume":"13","author":"Diack","year":"2024","journal-title":"Transl Vis Sci Technol"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526000679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526000679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:39:55Z","timestamp":1778924395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526000679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666914526000679"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101129","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Na\u00efve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101129"}}